Hcw Biologics Stock Performance
| HCWB Stock | USD 4.36 0.11 2.46% |
The firm retains a Market Volatility (i.e., Beta) of -0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning HCW Biologics are expected to decrease at a much lower rate. During the bear market, HCW Biologics is likely to outperform the market. At this point, HCW Biologics has a negative expected return of -0.3%. Please make sure to check out HCW Biologics' accumulation distribution, as well as the relationship between the day typical price and relative strength index , to decide if HCW Biologics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days HCW Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.36) | Five Day Return (10.00) | Year To Date Return (76.13) | Ten Year Return (98.29) | All Time Return (98.29) |
Last Split Factor 1:40 | Last Split Date 2025-04-11 |
1 | Acquisition by Greene Rick S. of 481 shares of HCW Biologics at 26.0 subject to Rule 16b-3 | 05/07/2025 |
2 | Acquisition by Greene Rick S. of 962 shares of HCW Biologics at 26.0 subject to Rule 16b-3 | 05/08/2025 |
3 | Trading Resumes for HCW Biologics HCWB Stock News | 05/13/2025 |
4 | Acquisition by Hing Wong of 46250 shares of HCW Biologics at 26.0 subject to Rule 16b-3 | 05/27/2025 |
5 | HCW Biologics Engages Armistice in Securities Purchase - TipRanks | 05/30/2025 |
6 | HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech | 06/04/2025 |
7 | HCW Biologics Sees Strong Investor Interest in June - TipRanks | 06/13/2025 |
8 | Acquisition by Hing Wong of 2000 shares of HCW Biologics at 1.546 subject to Rule 16b-3 | 06/18/2025 |
9 | HCW Biologics jumps 16 percent on pricing 5M follow on offering - MSN | 06/24/2025 |
10 | HCWB Regains Nasdaq Compliance Meeting All Listing Standards HCWB Stock News | 06/26/2025 |
11 | Insider Purchases Worth US3.05m See Losses As HCW Biologics Market Value Drops To US7.8m | 07/01/2025 |
12 | HCW Biologics Inc. Stock Analysis and Forecast - High-profit trading signals - Jammu Links News | 07/18/2025 |
13 | What analysts say about HCW Biologics Inc. stock - Exceptional growth trajectory - Autocar Professional | 07/21/2025 |
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | -261.6 K |
HCW Biologics Relative Risk vs. Return Landscape
If you would invest 794.00 in HCW Biologics on April 24, 2025 and sell it today you would lose (347.00) from holding HCW Biologics or give up 43.7% of portfolio value over 90 days. HCW Biologics is currently does not generate positive expected returns and assumes 13.4684% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than HCW, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
HCW Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HCW Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HCW Biologics, and traders can use it to determine the average amount a HCW Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0225
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HCWB |
Estimated Market Risk
| 13.47 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average HCW Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HCW Biologics by adding HCW Biologics to a well-diversified portfolio.
HCW Biologics Fundamentals Growth
HCW Stock prices reflect investors' perceptions of the future prospects and financial health of HCW Biologics, and HCW Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HCW Stock performance.
| Return On Equity | -277.26 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (782.98) % | ||||
| Current Valuation | 23.8 M | ||||
| Shares Outstanding | 2.54 M | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 7.59 X | ||||
| Revenue | 2.57 M | ||||
| Gross Profit | 345.67 K | ||||
| EBITDA | (27.68 M) | ||||
| Net Income | (30.02 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 13.69 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (7.62) X | ||||
| Cash Flow From Operations | (14.23 M) | ||||
| Earnings Per Share | (24.80) X | ||||
| Market Capitalization | 10.97 M | ||||
| Total Asset | 30.24 M | ||||
| Retained Earnings | (100.56 M) | ||||
| Working Capital | (23.93 M) | ||||
About HCW Biologics Performance
By analyzing HCW Biologics' fundamental ratios, stakeholders can gain valuable insights into HCW Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HCW Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HCW Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 141.58 | 134.50 | |
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (48.51) | (46.09) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | 4.43 | 4.66 |
Things to note about HCW Biologics performance evaluation
Checking the ongoing alerts about HCW Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HCW Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HCW Biologics generated a negative expected return over the last 90 days | |
| HCW Biologics has high historical volatility and very poor performance | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.57 M. Net Loss for the year was (30.02 M) with profit before overhead, payroll, taxes, and interest of 345.67 K. | |
| HCW Biologics currently holds about 32.41 M in cash with (14.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| HCW Biologics has a frail financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: What analysts say about HCW Biologics Inc. stock - Exceptional growth trajectory - Autocar Professional |
- Analyzing HCW Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HCW Biologics' stock is overvalued or undervalued compared to its peers.
- Examining HCW Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HCW Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HCW Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HCW Biologics' stock. These opinions can provide insight into HCW Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |